GLP-1 statistics and trends 2026

Why these numbers matter in 2026

GLP-1 statistics now cover diabetes treatment, chronic weight management, cardiovascular risk reduction, sleep apnea indications, Medicaid policy, employer benefits, online prescribing, compounding, counterfeit risk, pharmacy access, and daily patient behavior. A use statistic does not answer the same question as a price statistic. A shortage update does not answer the same question as an insurance rule.

The most reliable public numbers do not all answer the same question. KFF polling describes self-reported adult use and affordability. KFF Medicaid analysis describes state program coverage, prescriptions, and gross spending. FDA pages describe approval, shortage, compounding, and safety concerns. Company materials describe specific products and launches. Public interest and news volume can show attention, but they do not prove use. Each source has to be read for what it can actually support.

Approval, availability, coverage, and personal fit are not the same thing. A medicine can be FDA-approved and still be hard to afford. It can be listed as available while a local pharmacy has delays. It can be covered for diabetes but excluded for obesity. A product can have strong trial data and still be the wrong choice for a particular person.

How many adults use GLP-1 drugs?

KFF polling published in late 2025 found that 12% of adults said they were currently taking a GLP-1 drug such as Ozempic or Wegovy for weight loss, diabetes, or another condition. The same poll found that 18% said they had taken a GLP-1 drug at some point. Those two numbers answer different questions. Current use describes active treatment at the time of the survey. Ever use includes people who stopped because of cost, side effects, access, insurance, pregnancy planning, a clinician decision, or another reason.

The gap between current use and ever use matters because it suggests many people try these medicines without staying on them forever. Some stop because of cost. Some stop because of side effects, pharmacy problems, or a change in goals. Others restart after a coverage change or a switch in product. That is one reason it helps to keep a clear record of doses, appetite, symptoms, weight, meals, and questions, especially if treatment becomes uneven over time.

High use does not mean these medicines are right for everyone. It does show why so many people are now comparing prices, checking side effects, and asking harder questions about muscle loss, long-term access, and what happens if they stop.

How much do GLP-1 drugs cost?

GLP-1 cost questions usually come from practical pressure. A person may have a prescription but no coverage. They may have coverage for diabetes but not obesity. They may have a coupon that changes after a few months. They may see a direct-to-consumer subscription price that does not match the pharmacy counter. They may be weighing an FDA-approved product against a compounded offer and trying to understand the risk.

KFF reported that 56% of users said GLP-1 drugs were difficult to afford. That is why cost questions now sit near the center of the GLP-1 conversation. The most useful answer keeps the date, product, source, insurance setting, and country attached to every number, then checks the exact medication, indication, plan rules, pharmacy benefit, coupon eligibility, prior authorization, quantity limit, and refill timing.

If you are paying out of pocket, the medicine often becomes part of a monthly budgeting decision rather than a simple pharmacy pickup. In that situation it helps to keep a clean record of doses, side effects, weight trend, meals, protein, hydration, and appointment questions. A record can support a clinician conversation or an insurance appeal, but it does not guarantee coverage.

Coverage is uneven across Medicaid programs

KFF reported that 13 state Medicaid programs covered GLP-1 drugs for obesity treatment under fee-for-service as of January 2026. That figure matters because Medicaid policy is one of the clearest examples of uneven access. A person’s coverage can depend on state decisions, managed care rules, the diagnosis attached to the prescription, prior authorization, and budget changes. A national statement about coverage can mislead if it hides those details.

Medicaid spending has also grown fast. KFF reported that Medicaid prescriptions for GLP-1 drugs rose from about 1 million in 2019 to more than 8 million in 2024, while gross spending rose from about $1 billion to almost $9 billion over the same period. Those figures explain why state coverage debates are intense. The medicines have real clinical uses, but program budgets face near-term cost pressure.

If you rely on Medicaid or another plan with strict rules, the most useful preparation is often practical rather than theoretical. Keep medication history, symptom notes, refill issues, and appointment questions in one place. That does not force a payer to cover a product, but it does make the timeline easier to explain when access suddenly changes.

Shortage status changed the compounding market

FDA shortage decisions are central to GLP-1 market reporting because they affect compounding policy. FDA determined that the shortage of tirzepatide injection products was resolved in 2024 and that the shortage of semaglutide injection products was resolved in 2025. FDA also set transition periods for certain compounders after the semaglutide shortage determination. Those policy details matter for anyone writing about compounded semaglutide or compounded tirzepatide in 2026.

The public conversation can be confusing because a national shortage decision does not mean every patient finds every dose easily at every local pharmacy. It also does not mean compounded copies are automatically allowed. The safest reading is to stay close to what FDA actually said, when it said it, and what that decision changes in practice. A legal or supply status is not personal medical advice.

FDA has also warned about fraudulent compounded semaglutide and tirzepatide marketed in the United States. The agency said some products contained false label information, including pharmacy names that did not match the actual source. That warning matters because growth in the category has also created more unsafe and misleading supply channels.

What do current public prices look like?

Public price examples are useful because they show how wide the spread can be before insurance enters the picture. In Lilly’s public Foundayo self-pay terms, a month of the lowest dose is listed at $149, while the highest strengths are listed at $349. In the United Kingdom, the Guardian reported that private-sale prices for Wegovy tablets ranged from £69 to £189 a month when the pill launched in July 2026. These are not universal patient costs. They are public examples tied to specific products, dates, and market settings.

The safest way to read those numbers is to keep the product, dose, country, and channel attached. A self-pay offer in the United States is not the same as a list price in another country. A private pharmacy price in the UK is not the same as NHS access. A daily tablet also should not be compared to a weekly injection as if the routine were identical.

What these numbers mean if you are thinking about starting

The biggest surprise for many people is that the medicine decision often turns into an access decision. The prescription itself is only one part of the question. The harder part may be whether the product is covered, whether the pharmacy can supply it, whether the price will hold after a savings offer changes, and whether the routine still feels manageable after the first month.

That is why it helps to think in two tracks at the same time. One track is clinical: what medicine, what goal, what side effects, what follow-up. The other is practical: what it costs, how it is taken, what to do if supply slips, and what you want written down before your next appointment. A clean record does not answer the clinical question for you, but it does make the conversation clearer.